EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, TCM Biotech International's Enterprise Value is NT$2,902.4 Mil.
TCM Biotech International's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-42.4 Mil. Therefore, TCM Biotech International's EV-to-FCF for today is -68.38.
The historical rank and industry rank for TCM Biotech International's EV-to-FCF or its related term are showing as below:
ROCO:4169'
s EV-to-FCF Range Over the Past 10 Years
Min: -75.13 Med: 29.94 Max: 255
Current: -67.26
During the past 13 years, the highest EV-to-FCF of TCM Biotech International was 255.00. The lowest was -75.13. And the median was 29.94.
ROCO:4169's EV-to-FCF is ranked worse than 100% of 370
companies
in the Biotechnology industry
Industry Median: 9.66
vs ROCO:4169: -67.26
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of TCM Biotech International's EV-to-FCF
For the Biotechnology subindustry, TCM Biotech International's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCM Biotech International's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCM Biotech International's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where TCM Biotech International's EV-to-FCF falls into.
TCM Biotech International's current Enterprise Value is NT$2,902.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TCM Biotech International's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-42.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCM Biotech International (ROCO:4169) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
TCM Biotech International's PE Ratio for today is calculated as:
TCM Biotech International's share price for today is NT$55.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TCM Biotech International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
TCM Biotech International EV-to-FCF Related Terms
Thank you for viewing the detailed overview of TCM Biotech International's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
TCM Biotech International (ROCO:4169) Business Description
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:4169 has been successfully added to your 